Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresMichal Juraska, James I. Mullins, Lindsay N. Carpp et al.|Proceedings of the National Academy of Sciences|2024Cited by 22
Bayesian estimation of HIV acquisition dates for prevention trialsRaabya Rossenkhan, Paul T. Edlefsen, Elena E. Giorgi et al.|mBio|2025Cited by 3
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresLawrence Corey, Carolyn Williamson, Hong Zhao et al.|Carolina Digital Repository (University of North Carolina at Chapel Hill)|2025Cited by 0